Loading...
•
Sep 30, 2025
Nuvectis Pharma Q3 2025 Earnings Report
Nuvectis Pharma reported higher operating expenses and a wider net loss in the third quarter of 2025 while increasing its cash balance year over year.
Key Takeaways
For Q3 2025, Nuvectis reported a net loss attributable to common shareholders of $9891000 and diluted EPS of -$0.44. Research and development expenses rose to $5774000 and general and administrative expenses were $2020000. Cash and cash equivalents increased to $35442000 as of September 30, 2025.
Net loss attributable to common shareholders was $9891000.
Research and development expenses totaled $5774000.
General and administrative expenses were $2020000.
Cash and cash equivalents increased to $35442000.
Forward Guidance
The company expects its cash runway to support operations into the third quarter of 2027 while advancing the NXP900 Phase 1b program.
Positive Outlook
- Cash runway expected into 3Q 2027.
- Phase 1b monotherapy study underway.
- Combination portion of Phase 1b expected by year-end.
- Completed Phase 1a dose escalation study.
- Clinical drug-drug interaction study successfully completed.
Challenges Ahead
- Continued operating losses.
- Increased R&D expenses year over year.
- Dependence on successful clinical milestones.
- No revenue generation.
- Exposure to future financing needs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...